Current Medical Research and Opinion最新文献

{"title":"Real-world effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol in Chinese patients with symptomatic chronic obstructive pulmonary disease (COPD): a post-marketing, prospective, multicenter, observational study.","authors":"Jinfang Ma, Fangfang Dou, Wutie Zhou, Liyu Li, Junfei Zhu, Yupeng Zhang, Luqian Zhou, Lin Su, Lu Dong, Yifan He, Ark Ye, David Slade, Jinping Zheng","doi":"10.1080/03007995.2025.2536600","DOIUrl":"10.1080/03007995.2025.2536600","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) in symptomatic chronic obstructive pulmonary disease (COPD) under real-world settings in China.</p><p><strong>Methods: </strong>In this single-arm, prospective, observational study, participants received 12 weeks of FF/UMEC/VI treatment. The primary outcome was change from baseline (CFB) in COPD Assessment Test (CAT) score at Week 12. Secondary outcomes included CFB in modified Medical Research Council (mMRC) dyspnea scale score and pre-dose forced expiratory volume in one second (FEV₁), and proportion of CAT responders at Week 12.</p><p><strong>Results: </strong>From 14 October 2022 to 25 June 2023, 460 participants were enrolled; 392 (85.2%) completed the study treatment. After a 12-week treatment, there was a clinically meaningful CFB in CAT score with a mean of -6.81 (95% CI = -7.28-6.33); the proportion of CAT responders (≥2 points reduction from baseline) was 86%; the mean CFB in mMRC score was -0.52 (95% CI = -0.60∼-0.43); and pre-dose FEV₁ showed a clinically meaningful improvement from baseline with a mean of 0.13 L (95% CI = 0.10 ∼ 0.16). During the treatment, 10 (2.2%) participants reported FF/UMEC/VI-related adverse events.</p><p><strong>Conclusion: </strong>In real-world clinical practice in China, FF/UMEC/VI effectively improved symptoms and lung function in patients with symptomatic COPD and was well-tolerated.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1363-1372"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking histological healing to quality of life: real-world insights into golimumab therapy in ulcerative colitis.","authors":"Rodrigo Galhardi Gasparini, Carlos Taxonera, Antônio José Tibúrcio Alves Júnior, Bianca Loyo Pona Schiavetti, Francisco Guilherme Cancela E Penna, Richard Borba Magalhães, Sandro da Costa Ferreira, Renata de Sá Brito Fróes, Carlos Henrique Marques Dos Santos, Cristina Flores, Bruno César da Silva, Rogério Serafim Parra, Alexandre Venâncio, Hélio Rzetelna, Carlos Frederico Pereira Porto Alegre Rosa, Adriana Ribas Andrade","doi":"10.1080/03007995.2025.2535454","DOIUrl":"10.1080/03007995.2025.2535454","url":null,"abstract":"<p><strong>Background: </strong>Ulcerative colitis (UC) significantly impacts patients' quality of life (QoL). Therapeutic strategies have increasingly focused on achieving histological and endoscopic remission in addition to clinical outcomes and patient-reported measures. Real-world data on the effectiveness of golimumab to achieve histologic remission is scarce.</p><p><strong>Methods: </strong>This was a multicenter, cohort study including 73 patients with moderate-to-severe UC treated with golimumab across Brazilian centers. Outcomes were assessed at weeks 24 and 54 and included histological remission (Nancy histological index [NHI]), endoscopic remission (Mayo endoscopic subscore [MES]), inflammatory biomarkers (CRP and fecal calprotectin), and QoL (IBDQ-36). Correlations between histological scores with endoscopic outcomes and QoL were analyzed using Spearman test.</p><p><strong>Results: </strong>At week 24, 32.4% of patients achieved complete histological remission (NHI grade 0), and 80.8% achieved endoscopic remission (MES 0 or 1). At week 54, 55.2% of patients had histological remission and 84.4% of patients achieved endoscopic remission. Mean CRP levels decreased from 13.16 mg/dL at baseline to 1.35 mg/dL at week 54 (<i>p</i> < 0.001), and mean calprotectin decreased from 2113.2 to 106.9 mcg/g (<i>p</i> < 0.001). QoL significantly improved, with IBDQ-36 scores increasing from 121.5 at baseline to 182.1 at week 24 and 194.2 at week 54 (<i>p</i> = 0.002). Significant correlations were observed between NHI with MES and IBDQ-36 at week 24.</p><p><strong>Conclusion: </strong>Golimumab has achieved sustained efficacy in the induction of histological and endoscopic remission and improvement in QoL in patients with moderate-to-severe UC in a real-world setting. These results support the use of golimumab as an effective, patient-centered therapeutic option, particularly when multidimensional disease control is the goal.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1219-1226"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic burden and treatment patterns among patients with mantle cell lymphoma in the United States: a retrospective study of administrative claims data.","authors":"Mahek Garg, Ambika Satija, Yan Song, Eric M Sarpong, Benjamin Meade, James Signorovitch, Katherine Ryland, Monika Raut","doi":"10.1080/03007995.2025.2536612","DOIUrl":"10.1080/03007995.2025.2536612","url":null,"abstract":"<p><strong>Objective: </strong>Mantle cell lymphoma (MCL) is a rare, aggressive form of non-Hodgkin's lymphoma with relatively poor prognosis. The economic burden of MCL warrants further evaluation, especially given an evolving treatment landscape. This study describes current treatment patterns and economic outcomes among patients with MCL in the United States.</p><p><strong>Methods: </strong>This retrospective cohort study identified adult patients with MCL from claims data (October 2015- March 2021). Outcomes included treatment patterns by line of therapy (LOT), monthly healthcare resource use (HRU) rates, and healthcare costs per patient per month (PPPM) overall and in first line (1 L), second line (2 L), third line (3 L), and beyond (3 L+).</p><p><strong>Results: </strong>The study included 696 patients with MCL (mean follow-up: 22 months; mean age: 71 years; 68% male). Bendamustine-based therapies were most common in 1 L (49%), followed by rituximab monotherapy (14%) and R-CHOP (13%). Rituximab monotherapy and ibrutinib-based therapies were the most common in 2 L (27%; 25%) and 3 L (33%; 21%). During follow-up, MCL-related visits accounted for most hospitalizations (69.2%) and >80% of total all-cause costs ($21,477/$25,944 PPPM). Mean total all-cause costs PPPM increased across lines (1 L: $29,301; 2 L: $34,667; 3 L+: $41,423) due to rising MCL-related medical costs (1 L: $23,859; 2 L: $27,933; 3 L+: $33,399). MCL-related hospitalization costs accounted for higher proportions of MCL-related medical costs with increasing LOTs (51.1% in 1 L to 70.0% in 3 L+).</p><p><strong>Conclusions: </strong>Although a range of treatments are used to manage MCL, including targeted therapies such as ibrutinib, there is a high HRU and cost burden driven by disease-related medical costs that increase with subsequent LOTs.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1227-1238"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician and patient perspectives on the treatment of hypercholesterolaemia: a cross-sectional study to identify disconnects.","authors":"Adie Viljoen, Vivian Auyeung, Holly Foot, Chloe Grimmett, Silvia Bodini, Laura Douglas, Tamara Kaloti, Zoe Moon, Richa Chhabra, Emma Cotterill, Daniel Robinson, Alberico Catapano, Leonardo De Luca, Tim Hollstein, Jules Payne, Matteo Pirro, Anja Vogt, Rob Horne","doi":"10.1080/03007995.2025.2538748","DOIUrl":"10.1080/03007995.2025.2538748","url":null,"abstract":"<p><strong>Objectives: </strong>Implementation of more stringent LDL-C targets, as recommended by ESC/EAS guidelines, may be influenced by physician understanding of patient preferences. We aimed to understand patient preferences for lipid lowering therapy (LLT) management, perceptions of LLT and unmet needs, alongside physician predictions. We also investigated physician and patient therapy choices in two clinical scenarios.</p><p><strong>Methods: </strong>450 physicians (224 primary care and 226 specialists) across Germany, Italy, and the UK were analysed.</p><p><strong>Results: </strong>Patients reported a high prevalence of unmet needs in relation to support with treatment which was not apparent to physicians. Clinicians underestimated the proportion of patients with doubts about their perceived need for LLT (predicted 40%; actual 64%), treatment concerns (predicted 40%; actual 78.7%), and unmet information needs (32% physician agreement; actual 75%). Despite having negative attitudes to existing treatments, 82% of patients were open to treatment intensification if their LLT was suboptimal (vs. 55% physician agreement). Furthermore, only 16.7% of patients believed repeated prescription changes would lead to non-adherence (vs. 52.4% physician agreement). Presented with case studies, physicians chose progressive LLT more often for the high CV risk case with statin intolerance than for the very high CV risk uncontrolled case (82.7% vs. 61.6%). In both cases, approximately 50% of patients chose progressive LLT.</p><p><strong>Conclusion: </strong>More comprehensive physician and patient support is needed to optimize LLT treatment. This should address patient and clinician barriers to treatment escalation and facilitate shared decision-making.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1291-1302"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of health conditions associated with higher risk for severe respiratory syncytial virus, influenza, or COVID-19.","authors":"Abby Hitchens, Sean D Candrilli, Justin Carrico, Katherine A Hicks, Eleanor Wilson, Darshan Mehta, Catherine A Panozzo, Parinaz Ghaswalla","doi":"10.1080/03007995.2025.2535456","DOIUrl":"10.1080/03007995.2025.2535456","url":null,"abstract":"<p><strong>Objective: </strong>Respiratory syncytial virus (RSV), influenza virus, and SARS-CoV-2 cause significant morbidity and mortality. Understanding the prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19, and demographic trends in multi-morbidity prevalence, may help inform effective interventional strategies against these respiratory infections in high-risk populations.</p><p><strong>Methods: </strong>This study analyzed data from the National Health and Nutrition Examination Survey (NHANES) database (2017-2018) from a representative sample of US adults (≥20 years).</p><p><strong>Results: </strong>Of 239 million surveyed adults, 44.5% had ≥1 underlying condition associated with higher risk of severe RSV, influenza, or COVID-19; this proportion increased to 72.2% of adults if 2 additional underlying conditions were also considered (hypertension and smoking; both associated risk factors for severe COVID-19). Among older adults (≥60 years), the majority had ≥1 underlying condition associated with higher risk for severe RSV, influenza, or COVID-19. Across different racial/ethnic groups, overall prevalence of ≥2 conditions was highest among individuals of Other Race (including multiracial) at 19.5%, followed by non-Hispanic Black (18.9%), non-Hispanic White (18.5%), Mexican-American/Other Hispanic (10.3%), and non-Hispanic Asian individuals (7.7%). Notably, non-Hispanic Black individuals had a higher prevalence of ≥1 underlying condition compared with other race/ethnicity groups across all age groups <75 years.</p><p><strong>Conclusions: </strong>These findings indicate increased prevalence of underlying health conditions associated with higher risk of severe RSV, influenza, or COVID-19 among older adults (≥60 years) and disproportionate prevalence among younger non-Hispanic Black individuals. Understanding racial and ethnic disparities in multi-morbidity prevalence of underlying conditions can inform public health interventions that target these respiratory viruses.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1353-1361"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of patient-reported outcome measures for platysma prominence.","authors":"Julia K Garcia, Rene M Hopfinger, Catherine Foley, Julie Whyte, Martha Gauthier, Brandon Foster, Vaishali Patel","doi":"10.1080/03007995.2025.2537898","DOIUrl":"10.1080/03007995.2025.2537898","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Platysma prominence (PP) is characterized by vertical bands along the length of the neck and blunting of the jawline, impacting aesthetic appearance. No validated patient-reported outcome (PRO) measures are available to assess patient experiences specific to PP.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Develop and validate fit-for-purpose PRO measures that capture patient experiences with PP and treatment outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;PRO measures were developed and validated in alignment with the FDA's patient-focused drug development guidance. Three interviews (concept elicitation [CE], &lt;i&gt;N&lt;/i&gt; = 30; cognitive debriefing [CD] round 1, &lt;i&gt;N&lt;/i&gt; = 20; round 2, &lt;i&gt;N&lt;/i&gt; = 5) were conducted with treatment-naive and previously treated adults with PP. Instruments were drafted based on concepts emerging from CE interviews. Psychometric testing for reliability and validity was conducted using phase 2 PP treatment study (ClinicalTrials.gov; NCT03915067) data (&lt;i&gt;N&lt;/i&gt; = 164). While there were no available gold standard measures, convergent and known-groups validity were assessed using multiple FACE-Q modules, the Participant Global Impression of Severity (PGIS)-Jawline, and the Participant Global Impression of Treatment Satisfaction (PGI-TS). The 2-way random intraclass correlation coefficient ICC(2,1) and R&lt;sub&gt;λ&lt;/sub&gt; were calculated to evaluate test-retest reliability. Values of ≥0.70 were considered success for both the ICC(2,1) and R&lt;sub&gt;λ&lt;/sub&gt;. Spearman correlations (ρ) between scores from draft instruments and co-validators were used to assess convergent validity (|ρ|≥0.40). Additionally, internal consistency reliability was examined for multi-item measures where Cronbach's α ≥ 0.70 was considered success.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;\"Bands\" or a variation (e.g., cords, ridges, lines) were the most common terms used to describe PP, reported by 50% of participants. The most frequently reported psychosocial impacts were looking older than desired (&lt;i&gt;n&lt;/i&gt; = 28, 93.3%), feeling self-conscious (&lt;i&gt;n&lt;/i&gt; = 24, 80.0%), feeling less attractive (&lt;i&gt;n&lt;/i&gt; = 20, 66.7%), and looking less attractive and dressing differently (both: &lt;i&gt;n&lt;/i&gt; = 19, 63.3%). Reduced platysma band prominence was the most cited change that would increase satisfaction (&lt;i&gt;n&lt;/i&gt; = 15, 50.0%). Following CE interviews, 3 PRO measures were drafted: Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts, ANLFQ: Satisfaction (Baseline/Follow-up), and the Bother Assessment Scale-Platysma Prominence (BAS-PP). CD interviews indicated that participants found the questionnaires understandable and relevant. In psychometric testing, established criteria for reliability and validity were predominantly met, with some exceptions. Three correlations were under the 0.40 threshold, and while these correlations were all in the expected direction, their smaller magnitudes were not unexpected given the restricted conceptual alignment between the PP PR","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1277-1290"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of intranasal dexmedetomidine on perioperative comfort evaluated using the General Comfort Questionnaire.","authors":"Jian Zheng, Fu-Qiang Chen, Yan Yang, Kang Wang, Jun Wang, Hai-Rong Gong","doi":"10.1080/03007995.2025.2545512","DOIUrl":"10.1080/03007995.2025.2545512","url":null,"abstract":"<p><strong>Objectives: </strong>Impaired clinical comfort has been shown to compromise in-hospital care quality and patient safety metrics. Therefore, optimizing perioperative comfort through evidence-based multimodal interventions has emerged as a paramount clinical priority in contemporary surgical and anesthesia practice. This study aimed to investigate the effects of intranasal administration of dexmedetomidine hydrochloride on comfort improvement in patients who underwent neuraxial anesthesia or nerve block anesthesia and to explore the risk factors for discomfort.</p><p><strong>Methods: </strong>We retrospectively analyzed cohort data from 350 patients who underwent neuraxial anesthesia or nerve block anesthesia at Xuzhou Renci Hospital between January and September 2024. The patients were divided into a control group and a dexmedetomidine group on the basis of whether intranasal administration of dexmedetomidine hydrochloride was used. The primary endpoint was the General Comfort Questionnaire (GCQ) score after surgery. The secondary endpoints included the VAS score, the Pittsburgh Sleep Quality Index (PSQI) score, and changes in blood pressure and heart rate. A multivariable logistic regression model was used to screen for risk factors associated with discomfort.</p><p><strong>Results: </strong>In this study, 200 patients underwent conventional anesthesia, and the remaining 150 patients were first administered dexmedetomidine hydrochloride intranasally before anesthesia induction. At various time points after surgery, the GCQ scores of patients in the dexmedetomidine group were consistently higher than those of patients in the control group (<i>p</i> < 0.001). The mean arterial blood pressure, heart rate, PSQI score, and VAS score were lower in the dexmedetomidine group than in the control group (<i>p</i> < 0.001). In the multivariable analysis, intervention (OR, 0.01; 95% CI, 0.00-0.05), age (OR, 1.17; 95% CI, 1.11-1.24), male sex (OR, 0.62; 95% CI, 0.41-0.95), sleep quality (OR, 1.57; 95% CI, 1.38-1.79) and pain catastrophizing scale score (OR, 1.08; 95% CI, 1.02-1.14) were independently associated with the GCQ score.</p><p><strong>Conclusions: </strong>These findings indicate that intranasal administration of dexmedetomidine hydrochloride significantly enhanced patient comfort, as evidenced by elevated GCQ scores, reduced VAS scores, and significantly improved postoperative sleep quality. Age, sex, sleep quality and pain catastrophizing scale scores were found to be independent factors for discomfort.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1135-1147"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022).","authors":"Amy Colson, Megan Chen, Fritha Hennessy, Joshua Gruber, Woodie Zachry, Seojin Park, Tim Holbrook","doi":"10.1080/03007995.2025.2517692","DOIUrl":"10.1080/03007995.2025.2517692","url":null,"abstract":"<p><strong>Objective: </strong>This study compared outcomes reported by health care providers (HCPs) and people with HIV (PWH) for individuals prescribed bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus other antiretroviral therapy (ART) regimens.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World HIV Disease Specific Programme, an observational, cross-sectional survey of HCPs and PWH conducted from July 2021-March 2022 in the United States. PWH were aged ≥18 years with confirmed HIV and a current ART prescription. Outcomes included HCP- and PWH-reported adherence, treatment satisfaction, quality of life (QoL), and health care resource utilization (HCRU). Subgroups for the primary analysis were based on ART regimen. Comparisons between subgroups were performed using appropriate statistical tests.</p><p><strong>Results: </strong>Sixty HCPs provided data for 600 PWH, and 249 PWH reported their experiences. Overall, 264 PWH were prescribed B/F/TAF, 281 were prescribed other single-tablet regimens or a long-acting injectable (STRs/LAI), and 55 were prescribed a multi-tablet regimen. Common HCP-reported reasons for choice of ART were viral potency and tolerability. High treatment satisfaction was reported for B/F/TAF by HCPs (61% \"very satisfied\" with B/F/TAF vs 53% with other STRs/LAI; <i>p</i> = 0.0223) and PWH (57% vs 52%, respectively; <i>p</i> = 0.3170). PWH receiving B/F/TAF reported significantly higher QoL and lower activity impairment versus PWH receiving other STRs/LAI. Adherence rates and HCRU were generally similar between groups.</p><p><strong>Conclusion: </strong>Positive HCP- and PWH-reported outcomes were seen across ART regimens. However, differences observed, including HCP-reported treatment satisfaction and PWH-reported QoL, favored B/F/TAF compared with other STRs/LAI. Findings support continued use of B/F/TAF for HIV treatment in the United States.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1319-1331"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of educational intervention to promote blood pressure control amongst hypertensive patients in a rural area of Delhi, India.","authors":"Anubhav Mondal, Richa Kapoor","doi":"10.1080/03007995.2025.2536603","DOIUrl":"10.1080/03007995.2025.2536603","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is a major cause of cardiovascular disease, with suboptimal control in low-income settings. In India, only 22.5% had controlled blood pressure (2016-2020). Educational technologies enhance adherence to treatment and lifestyle changes. This study evaluated an educational intervention's effectiveness in improving blood pressure control in rural Delhi.</p><p><strong>Materials and methods: </strong>A quasi-experimental study at Rural Health and Training Centre, Najafgarh, Delhi, assessed hypertensive patients in the Non-Communicable Disease Clinic. The intervention included flipchart counselling, weekly voice messages, and text reminders on self-care and adherence. Participants over 30 years had blood pressure, weight, and height measured at baseline and follow-ups (2, 4, 6 months). Data analysis used validated scales and SPSS 21.0.</p><p><strong>Results: </strong>A total of 110 participants were enrolled, with 102 completing the study. At baseline, the mean systolic blood pressure (SBP) was 151.1 mmHg and diastolic blood pressure (DBP) was 87.5 mmHg. SBP decreased significantly over the follow-ups, from 151.1 mmHg to 138.3 mmHg (<i>p</i> < 0.001), and DBP decreased from 87.5 mmHg to 82.8 mmHg (<i>p</i> < 0.001). The proportion of participants with controlled blood pressure increased from 14.7% at baseline to 52.9% at 6 months (<i>p</i> < 0.001). Further, weight loss was associated with improved blood pressure control.</p><p><strong>Conclusion: </strong>The educational intervention effectively improved blood pressure control among hypertensive patients in a rural setting. The study highlights the importance of lifestyle modifications, particularly weight management, in controlling hypertension. This approach could be upscaled to enhance hypertension management and also can be used in resource limited settings.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1165-1171"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient preferences for food allergy treatments in the United States: a discrete choice experiment.","authors":"Alexis T Mickle, Christopher M Warren, Arpamas Seetasith, Karissa M Johnston, Jessica S Dunne, Stacey Kowal, Andrea Bever, Stella Ko, Vincent Garmo, Sachin Gupta, Andrew Lloyd, Christina E Ciaccio","doi":"10.1080/03007995.2025.2544596","DOIUrl":"10.1080/03007995.2025.2544596","url":null,"abstract":"<p><strong>Objective: </strong>To estimate preferences of adolescents and caregivers of children with food allergies (FA) for food allergy for attributes for treatments intended to prevent exposure-induced severe reactions and to examine how these vary by clinical and demographic factors.</p><p><strong>Methods: </strong>A discrete choice experiment (DCE) was conducted between May and June 2024 among US-resident individuals, aged 13-17 years or caregivers of a child with FA aged ≤12 years, self-reporting physician-diagnosed FA. The survey comprised treatment-attribute focused DCE choice sets; the Intolerance of Uncertainty-12 Scale (IUS-12); the Food Allergy Independent Measure (FAIM); and clinical/demographic questions. Conditional logistic regression analyses were conducted overall and among subgroups and presented as odds ratios (ORs) with 95% confidence intervals (CIs). Relative importance of attributes was also calculated.</p><p><strong>Results: </strong>Participants were adolescents (<i>n</i> = 73, mean age 15.9 years) and caregivers (<i>n</i> = 228, mean age 37.1 years). Overall, treatment attributes associated with statistically significant odds for preferring a treatment included a 95% relative reduction in moderate-to-severe allergic reaction risk <i>versus</i> no reduction (<i>p</i> < 0.001); oral administration over subcutaneous (<i>p</i> < 0.001); administration in a home <i>versus</i> clinical setting (<i>p</i> < 0.05); less frequent <i>versus</i> daily administration (every two weeks: <i>p</i> < 0.001; every four weeks: <i>p</i> < 0.001). Respondents were disinclined to prefer treatment attributes when the risk of gastrointestinal symptoms (<i>p</i> < 0.001) or anaphylaxis (<i>p</i> < 0.001) increased. Efficacy (75% decrease in relative risk of a moderate-to-severe allergic reaction) was the top ranked attribute [OR = 1.61 (1.49, 1.75)].</p><p><strong>Conclusion: </strong>Overall, respondents indicated significant preferences for more efficacious, safer, and convenient (oral, at-home, and less frequent) treatments. Treatment efficacy was the most highly ranked treatment feature.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1303-1318"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}